Alzheimer’s disease genetic risk factor APOE-ε4 also affects normal brain function

Current Alzheimer Research

Volumn 13, Issue 11, 2016, Pages 1200-1207

  DiBattista, Amanda M ^a   Heinsinger, Nicolette M ^a   Rebeck, G William ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amyloid; Apolippoprotein E; Dendritic spine; Entorhinal cortex; Hippocampus; Prevention; Risk factor; Targeted replacement mice

Indexed keywords

APOPROTEIN; APOPROTEIN EPSILON 4; ISOPROTEIN; UNCLASSIFIED DRUG; APOLIPOPROTEIN E4;

ALZHEIMER DISEASE; BEHAVIOR; BRAIN; BRAIN FUNCTION; EXCITABILITY; GENETIC RISK; GENOTYPE; HUMAN; NERVOUS SYSTEM INFLAMMATION; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; ANIMAL; DIAGNOSTIC IMAGING; GENETICS; METABOLISM; MOUSE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RISK FACTOR;

ALZHEIMER DISEASE; ANIMALS; APOLIPOPROTEIN E4; BRAIN; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; RISK FACTORS;

EID: 84995745550     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205013666160401115127     Document Type: Review

References (123)

1. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 367(9): 795-804 (2012).
2. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313(19): 1924-38 (2015).
3. Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer’s disease: implications for prevention trials. Neuron 84(3): 608-22 (2014).
4. Quiroz YT, Schultz AP, Chen K, Protas HD, Brickhouse M, Fleisher AS, et al. Brain imaging and blood biomarker abnormalities in children with autosomal dominant Alzheimer disease: a cross-sectional study. JAMA Neurol 72(8): 912-9 (2015).
5. Mahley RW, Rall SC, Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genom Hum Genet 1: 507-37 (2000).
6. Serrano-Pozo A, Qian J, Monsell SE, Betensky RA, Hyman BT. APOEepsilon2 is associated with milder clinical and pathological Alzheimer disease. Ann Neurol 77(6): 917-29 (2015).
7. Naj AC, Jun G, Reitz C, Kunkle BW, Perry W, Park YS, et al. Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. JAMA Neurol 71(11): 1394-404 (2014).
8. Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, Ahern GL, et al. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med 361 (3): 255-63 (2009).
9. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol 12(4): 357-67 (2013).
10. Nelson PT, Pious NM, Jicha GA, Wilcock DM, Fardo DW, Estus S, et al. APOE-epsilon2 and APOE-epsilon4 correlate with increased amyloid accumulation in cerebral vasculature. J Neuropathol Exp Neurol 72(7): 708-15 (2013).
11. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer’s disease: allelic variation and receptor interactions. Neuron 11(4): 575-80 (1993).
12. Tai LM, Bilousova T, Jungbauer L, Roeske SK, Youmans KL, Yu C, et al. Levels of soluble apolipoprotein E/amyloid-beta (Abeta) complex are reduced and oligomeric Abeta increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J Biol Chem 288(8): 5914-26 (2013).
13. Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Palsson E, et al. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. JAMA Psychiatry 71(10): 1183-91 (2014).
14. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer’s disease. Neuron 63(3): 287-303 (2009).
15. Youmans KL, Tai LM, Nwabuisi-Heath E, Jungbauer L, Kanekiyo T, Gan M, et al. APOE4-specific changes in Abeta accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem 287(50): 41774-86 (2012).
16. Manning EN, Barnes J, Cash DM, Bartlett JW, Leung KK, Ourselin S, et al. APOE epsilon4 is associated with disproportionate progressive hippocampal atrophy in AD. PLoS One 9(5): e97608 (2014).
17. Wolk DA, Dickerson BC, Neuroimaging AsD. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer’s disease. Proc Nat Acad Sci USA 107(22): 10256-61 (2010).
18. Huang Y, Mahley RW. Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer’s diseases. Neurobiol Dis 72 Pt A: 3-12 (2014).
19. Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science 294(5545): 1354-7 (2001).
20. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258(5081): 468-71 (1992).
21. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71(2): 343-53 (1992).
22. Mak AC, Pullinger CR, Tang LF, Wong JS, Deo RC, Schwarz JM, et al. Effects of the absence of apolipoprotein e on lipoproteins, neurocognitive function, and retinal function. JAMA Neurol 71(10): 1228-36 (2014).
23. Buttini M, Orth M, Bellosta S, Akeefe H, Pitas RE, Wyss-Coray T, et al. Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration. J Neurosci 19(12): 4867-80 (1999).
24. Hayek T, Oiknine J, Brook JG, Aviram M. Increased plasma and lipoprotein lipid peroxidation in apo E-deficient mice. Biochem Biophys Res Commun 201(3): 1567-74 (1994).
25. Raffai RL, Dong LM, Farese RV, Jr., Weisgraber KH. Introduction of human apolipoprotein E4 “domain interaction” into mouse apolipoprotein E. Proc Natl Acad Sci USA 98(20): 11587-91 (2001).
26. Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, et al. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 272(29): 17972-80 (1997).
27. Sullivan PM, Mace BE, Maeda N, Schmechel DE. Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice. Neuroscience 124(4): 725-33 (2004).
28. Wang C, Wilson WA, Moore SD, Mace BE, Maeda N, Schmechel DE, et al. Human apoE4-targeted replacement mice display synaptic deficits in the absence of neuropathology. Neurobiol Dis 18(2): 390-8 (2005).
29. Liraz O, Boehm-Cagan A, Michaelson DM. ApoE4 induces Abeta42, tau, and neuronal pathology in the hippocampus of young targeted replacement apoE4 mice. Mol Neurodegener 8: 16 (2013).
30. Rodriguez GA, Burns MP, Weeber EJ, Rebeck GW. Young APOE4 targeted replacement mice exhibit poor spatial learning and memory, with reduced dendritic spine density in the medial entorhinal cortex. Learn Mem 20(5): 256-66 (2013).
31. Salomon-Zimri S, Boehm-Cagan A, Liraz O, Michaelson DM. Hippocampus-related cognitive impairments in young apoE4 targeted replacement mice. Neurodegener Dis 13(2-3): 86-92 (2014).
32. Bour A, Grootendorst J, Vogel E, Kelche C, Dodart JC, Bales K, et al. Middle-aged human apoE4 targeted-replacement mice show retention deficits on a wide range of spatial memory tasks. Behav Brain Res 193(2): 174-82 (2008).
33. Raber J, Wong D, Buttini M, Orth M, Bellosta S, Pitas RE, et al. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc Natl Acad Sci USA 95(18): 10914-9 (1998).
34. Raber J, Wong D, Yu GQ, Buttini M, Mahley RW, Pitas RE, et al. Apolipoprotein E and cognitive performance. Nature 404(6776): 352-4 (2000).
35. Siegel JA, Haley GE, Raber J. Apolipoprotein E isoform-dependent effects on anxiety and cognition in female TR mice. Neurobiol Aging 33(2): 345-58 (2012).
36. Dumanis SB, Tesoriero JA, Babus LW, Nguyen MT, Trotter JH, Ladu MJ, et al. ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. J Neurosci 29(48): 15317-22 (2009).
37. Andrews-Zwilling Y, Bien-Ly N, Xu Q, Li G, Bernardo A, Yoon SY, et al. Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. J Neurosci 30(41): 13707-17 (2010).
38. Klein RC, Acheson SK, Mace BE, Sullivan PM, Moore SD. Altered neurotransmission in the lateral amygdala in aged human apoE4 targeted replacement mice. Neurobiol Aging 35(9): 2046-52 (2014).
39. Korwek KM, Trotter JH, Ladu MJ, Sullivan PM, Weeber EJ. ApoE isoform-dependent changes in hippocampal synaptic function. Mol Neurodegener 4: 21 (2009).
40. Trommer BL, Shah C, Yun SH, Gamkrelidze G, Pasternak ES, Ye GL, et al. ApoE isoform affects LTP in human targeted replacement mice. Neuroreport 15(17): 2655-8 (2004).
41. Yong SM, Lim ML, Low CM, Wong BS. Reduced neuronal signaling in the ageing apolipoprotein-E4 targeted replacement female mice. Sci Rep 4: 6580 (2014).
42. Dumanis SB, DiBattista AM, Miessau M, Moussa CE, Rebeck GW. APOE genotype affects the pre-synaptic compartment of glutamatergic nerve terminals. J Neurochem 124(1): 4-14 (2013).
43. Kariv-Inbal Z, Yacobson S, Berkecz R, Peter M, Janaky T, Lutjohann D, et al. The isoform-specific pathological effects of apoE4 in vivo are prevented by a fish oil (DHA) diet and are modified by cholesterol. J Alzheimers Dis 28(3): 667-83 (2012).
44. Barger SW. Apolipoprotein E acts at pre-synaptic sites…among others. J Neurochem 124(1): 1-3 (2013).
45. Ward A, Crean S, Mercaldi CJ, Collins JM, Boyd D, Cook MN, et al. Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer’s disease: a systematic review and meta-analysis. Neuroepidemiology 38(1): 1-17 (2012).
46. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278(16): 1349-56 (1997).
47. Acevedo SF, Piper BJ, Craytor MJ, Benice TS, Raber J. Apolipoprotein E4 and sex affect neurobehavioral performance in primary school children. Pediatr Res 67(3): 293-9 (2010).
48. Berteau-Pavy F, Park B, Raber J. Effects of sex and APOE epsilon4 on object recognition and spatial navigation in the elderly. Neuroscience 147(1): 6-17 (2007).
49. Haley GE, Berteau-Pavy F, Parkv B, Raber J. Effects of epsilon4 on object recognition in the non-demented elderly. Curr Aging Sci 3(2): 127-37 (2010).
50. Yasen AL, Raber J, Miller JK, Piper BJ. Sex, but not apolipoprotein E polymorphism, differences in spatial performance in young adults. Arch Sex Behav 44(8): 2219-26 (2015).
51. Luck T, Then FS, Luppa M, Schroeter ML, Arelin K, Burkhardt R, et al. Association of the apolipoprotein E genotype with memory performance and executive functioning in cognitively intact elderly. Neuropsychology 29(3): 382-7 (2015).
52. Pendleton N, Payton A, van den Boogerd EH, Holland F, Diggle P, Rabbitt PM, et al. Apolipoprotein E genotype does not predict decline in intelligence in healthy older adults. Neurosci Lett 324(1): 74-6 (2002).
53. Taylor AE, Guthrie PA, Smith GD, Golding J, Sattar N, Hingorani AD, et al. IQ, educational attainment, memory and plasma lipids: associations with apolipoprotein E genotype in 5995 children. Biol Psychiatry 70(2): 152-8 (2011).
54. Yu YW, Lin CH, Chen SP, Hong CJ, Tsai SJ. Intelligence and event-related potentials for young female human volunteer apolipoprotein E epsilon4 and non-epsilon4 carriers. Neurosci Lett 294(3): 179-81 (2000).
55. Jochemsen HM, Muller M, van der Graaf Y, Geerlings MI. APOE epsilon4 differentially influences change in memory performance depending on age. The SMART-MR study. Neurobiol Aging 33(4): 832 e15-22 (2012).
56. Mondadori CR, de Quervain DJ, Buchmann A, Mustovic H, Wollmer MA, Schmidt CF, et al. Better memory and neural efficiency in young apolipoprotein E epsilon4 carriers. Cereb Cortex 17(8): 1934-47 (2007).
57. Rusted JM, Evans SL, King SL, Dowell N, Tabet N, Tofts PS. APOE e4 polymorphism in young adults is associated with improved attention and indexed by distinct neural signatures. Neuroimage 65: 364-73 (2013).
58. Tuminello ER, Han SD. The apolipoprotein e antagonistic pleiotropy hypothesis: review and recommendations. Int J Alzheimers Dis 2011: 726197 (2011).
59. Rusted J, Carare RO. Are the effects of APOE 4 on cognitive function in nonclinical populations age- and gender-dependent? Neurodegener Dis Manag 5(1): 37-48 (2015).
60. Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 298(11): 1300-11 (2007).
61. Vossel KA, Beagle AJ, Rabinovici GD, Shu H, Lee SE, Naasan G, et al. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol 70(9): 1158-66 (2013).
62. Briellmann RS, Torn-Broers Y, Busuttil BE, Major BJ, Kalnins RM, Olsen M, et al. APOE epsilon4 genotype is associated with an earlier onset of chronic temporal lobe epilepsy. Neurology 55(3): 435-7 (2000).
63. Diaz-Arrastia R, Gong Y, Fair S, Scott KD, Garcia MC, Carlile MC, et al. Increased risk of late posttraumatic seizures associated with inheritance of APOE epsilon4 allele. Arch Neurol 60(6): 818-22 (2003).
64. Ji Y, Gong Y, Gan W, Beach T, Holtzman DM, Wisniewski T. Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer’s disease patients. Neuroscience 122(2): 305-15 (2003).
65. Dean DC, 3rd, Jerskey BA, Chen K, Protas H, Thiyyagura P, Roontiva A, et al. Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study. JAMA Neurol 71(1): 11-22 (2014).
66. Knickmeyer RC, Wang J, Zhu H, Geng X, Woolson S, Hamer RM, et al. Common variants in psychiatric risk genes predict brain structure at birth. Cereb Cortex 24(5): 1230-46 (2014).
67. DiBattista AM, Stevens BW, Rebeck GW, Green AE. Two Alzheimer’s disease risk genes increase entorhinal cortex volume in young adults. Front Hum Neurosci 8: 779 (2014).
68. Dennis NA, Browndyke JN, Stokes J, Need A, Burke JR, Welsh- Bohmer KA, et al. Temporal lobe functional activity and connectivity in young adult APOE varepsilon4 carriers. Alzheimers Dement 6(4): 303-11 (2010).
69. Filippini N, Rao A, Wetten S, Gibson RA, Borrie M, Guzman D, et al. Anatomically-distinct genetic associations of APOE epsilon4 allele load with regional cortical atrophy in Alzheimer’s disease. Neuroimage 44(3): 724-8 (2009).
70. Matura S, Prvulovic D, Jurcoane A, Hartmann D, Miller J, Scheibe M, et al. Differential effects of the ApoE4 genotype on brain structure and function. Neuroimage 89: 81-91 (2014).
71. O’Dwyer L, Lamberton F, Matura S, Tanner C, Scheibe M, Miller J, et al. Reduced hippocampal volume in healthy young ApoE4 carriers: an MRI study. PLoS One 7(11): e48895 (2012).
72. Alexopoulos P, Richter-Schmidinger T, Horn M, Maus S, Reichel M, Sidiropoulos C, et al. Hippocampal volume differences between healthy young apolipoprotein E epsilon2 and epsilon4 carriers. J Alzheimers Dis 26(2): 207-10 (2011).
73. Fennema-Notestine C, Panizzon MS, Thompson WR, Chen CH, Eyler LT, Fischl B, et al. Presence of ApoE epsilon4 allele associated with thinner frontal cortex in middle age. J Alzheimers Dis 26(3): 49-60 (2011).
74. Espeseth T, Westlye LT, Fjell AM, Walhovd KB, Rootwelt H, Reinvang I. Accelerated age-related cortical thinning in healthy carriers of apolipoprotein E epsilon 4. Neurobiol Aging 29(3): 329-40 (2008).
75. Alexander GE, Bergfield KL, Chen K, Reiman EM, Hanson KD, Lin L, et al. Gray matter network associated with risk for Alzheimer’s disease in young to middle-aged adults. Neurobiol Aging 33(12): 2723-32 (2012).
76. Wishart HA, Saykin AJ, McAllister TW, Rabin LA, McDonald BC, Flashman LA, et al. Regional brain atrophy in cognitively intact adults with a single APOE epsilon4 allele. Neurology 67(7): 1221-4 (2006).
77. Fei M, Jianhua W. Apolipoprotein epsilon4-allele as a significant risk factor for conversion from mild cognitive impairment to Alzheimer’s disease: a meta-analysis of prospective studies. J Mol Neurosci 50(2): 257-63 (2013).
78. Shen L, Kim S, Risacher SL, Nho K, Swaminathan S, West JD, et al. Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. Neuroimage 53(3): 1051-63 (2010).
79. Thomann PA, Roth AS, Dos Santos V, Toro P, Essig M, Schroder J. Apolipoprotein E polymorphism and brain morphology in mild cognitive impairment. Dement Geriatr Cogn Disord 26(4): 300-5 (2008).
80. Knopman DS, Jack CR, Jr., Wiste HJ, Lundt ES, Weigand SD, Vemuri P, et al. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Neurobiol Aging 35(9): 2096-106 (2014).
81. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer’s disease. Proc Natl Acad Sci USA 98(6): 3334-9 (2001).
82. Scarmeas N, Habeck C, Anderson KE, Hilton J, Devanand DP, Pelton GH, et al. Altered PET functional brain responses in cognitively intact elderly persons at risk for Alzheimer disease (carriers of the epsilon4 allele). Am J Geriatr Psychiatry 12(6): 596-605(2004).
83. Scarmeas N, Habeck CG, Hilton J, Anderson KE, Flynn J, Park A, et al. APOE related alterations in cerebral activation even at college age. J Neurol Neurosurg Psychiatry 76(10): 1440-4 (2005).
84. Deeny SP, Poeppel D, Zimmerman JB, Roth SM, Brandauer J, Witkowski S, et al. Exercise, APOE, and working memory: MEG and behavioral evidence for benefit of exercise in epsilon4 carriers. Biol Psychol 78(2): 179-87 (2008).
85. Filippini N, MacIntosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM, et al. Distinct patterns of brain activity in young carriers of the APOE-epsilon 4 allele. Proc Natl Acad Sci USA 106(17): 7209-14(2009).
86. Borghesani PR, Johnson LC, Shelton AL, Peskind ER, Aylward EH, Schellenberg GD, et al. Altered medial temporal lobe responses during visuospatial encoding in healthy APOE*4 carriers. Neurobiol Aging 29(7): 981-91 (2008).
87. Green AE, Gray JR, Deyoung CG, Mhyre TR, Padilla R, Dibattista AM, et al. A combined effect of two Alzheimer’s risk genes on medial temporal activity during executive attention in young adults. Neuropsychologia 56: 1-8 (2014).
88. Kunz L, Schroder TN, Lee H, Montag C, Lachmann B, Sariyska R, et al. Reduced grid-cell-like representations in adults at genetic risk for Alzheimer’s disease. Science 350(6259): 430-3 (2015).
89. Filippini N, Ebmeier KP, MacIntosh BJ, Trachtenberg AJ, Frisoni GB, Wilcock GK, et al. Differential effects of the APOE genotype on brain function across the lifespan. Neuroimage 54(1): 602-10 (2011)
90. Chen CJ, Chen CC, Wu D, Chi NF, Chen PC, Liao YP, et al Effects of the apolipoprotein E epsilon4 allele on functional MRI during n-back working memory tasks in healthy middle-aged adults. AJNR Am J Neuroradiol 34(6): 1197-202 (2013).
91. Riddell DR, Zhou H, Atchison K, Warwick HK, Atkinson PJ, Jefferson J, et al. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci 28(45): 11445-53 (2008).
92. Sullivan PM, Han B, Liu F, Mace BE, Ervin JF, Wu S, et al. Reduced levels of human apoE4 protein in an animal model of cognitive impairment. Neurobiol Aging 32(5): 791-801 (2011).
93. Zhong N, Weisgraber KH. Understanding the basis for the association of apoE4 with Alzheimer’s disease: opening the door for therapeutic approaches. Curr Alzheimer Res 6(5): 415-8 (2009).
94. Cruchaga C, Kauwe JS, Nowotny P, Bales K, Pickering EH, Mayo K, et al. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer’s disease. Hum Mol Genet 21(20): 4558-71 (2012).
95. Martinez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP, et al. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer’s disease patients and controls. Acta Neuropathol 127(5): 633-43 (2014).
96. Rasmussen KL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke- Schmidt R. Plasma levels of apolipoprotein E and risk of dementia in the general population. Ann Neurol 77(2): 301-11 (2015).
97. Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Investig 76(4): 1501-13 (1985).
98. LaDu MJ, Gilligan SM, Lukens JR, Cabana VG, Reardon CA, Van Eldik LJ, et al. Nascent astrocyte particles differ from lipoproteins in CSF. J Neurochem 70(5): 2070-81 (1998).
99. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J Biol Chem 262(29): 14352-60 (1987).
100. Lee J, Bu G. Genetics and molecular biology: ABCA1 in brain apolipoprotein E metabolism and lipidation. Curr Opin Lipidol 16(1): 115-7 (2005).
101. Hu J, Liu CC, Chen XF, Zhang YW, Xu H, Bu G. Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Abeta metabolism in apoE4- targeted replacement mice. Mol Neurodegen 10: 6(2015).
102. Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, Mangelsdorf DJ, et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci USA 98(2): 507-12 (2001).
103. Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang S, Glorioso JC, et al. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer’s disease. J Biol Chem 280(6): 4079-88 (2005).
104. Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, et al. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer’s disease. Mol Cell Neurosci 34(4): 621-8 (2007).
105. Donkin JJ, Stukas S, Hirsch-Reinshagen V, Namjoshi D, Wilkinson A, May S, et al. ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. J Biol Chem 285(44): 34144-54 (2010).
106. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335(6075): 1503-6 (2012).
107. Corona AW, Kodoma N, Casali BT, Landreth GE. ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice. J Neuroimmune Pharmacol 11(1): 61-72 (2016).
108. Kim J, Yoon H, Horie T, Burchett JM, Restivo JL, Rotllan N, et al. microRNA-33 Regulates ApoE Lipidation and Amyloid-beta Metabolism in the Brain. J Neurosci 35(44): 14717-26 (2015).
109. Zhao J, Fu Y, Liu CC, Shinohara M, Nielsen HM, Dong Q, et al. Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway. J Biol Chem 289(16): 11282-92 (2014).
110. Li K, Ching D, Luk FS, Raffai RL. Apolipoprotein E enhances MicroRNA-146a in monocytes and macrophages to suppress nuclear factor-kappaB-driven inflammation and atherosclerosis. Circ Res 117(1): e1-e11 (2015).
111. Vitek MP, Brown CM, Colton CA. APOE genotype-specific differences in the innate immune response. Neurobiol Aging 30(9): 1350-60 (2009).
112. Pocivavsek A, Burns MP, Rebeck GW. Low-density lipoprotein receptors regulate microglial inflammation through c-Jun Nterminal kinase. Glia 57(4): 444-53 (2009).
113. Tu JL, Zhao CB, Vollmer T, Coons S, Lin HJ, Marsh S, et al. APOE 4 polymorphism results in early cognitive deficits in an EAE model. Biochem Biophys Res Commun 384(4): 466-70 (2009).
114. Friedman G, Froom P, Sazbon L, Grinblatt I, Shochina M, Tsenter J, et al. Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury. Neurology 52(2): 244-8 (1999).
115. Zhu Y, Nwabuisi-Heath E, Dumanis SB, Tai LM, Yu C, Rebeck GW, et al. APOE genotype alters glial activation and loss of synaptic markers in mice. Glia 60(4): 559-69 (2012).
116. Lynch JR, Tang W, Wang H, Vitek MP, Bennett ER, Sullivan PM, et al. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem 278(49): 48529-33 (2003).
117. Ophir G, Amariglio N, Jacob-Hirsch J, Elkon R, Rechavi G, Michaelson DM. Apolipoprotein E4 enhances brain inflammation by modulation of the NF-kappaB signaling cascade. Neurobiol Dis 20(3): 709-18 (2005).
118. Colton CA, Needham LK, Brown C, Cook D, Rasheed K, Burke JR, et al. APOE genotype-specific differences in human and mouse macrophage nitric oxide production. J Neuroimmunol 147(1-2):62-7 (2004).
119. Szekely CA, Breitner JC, Fitzpatrick AL, Rea TD, Psaty BM, Kuller LH, et al. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology 70(1): 17-24 (2008).
120. Hunter JM, Cirrito JR, Restivo JL, Kinley RD, Sullivan PM, Holtzman DM, et al. Emergence of a seizure phenotype in aged apolipoprotein epsilon 4 targeted replacement mice. Brain Res 1467: 120-32 (2012).
121. Bomben V, Holth J, Reed J, Cramer P, Landreth G, Noebels J. Bexarotene reduces network excitability in models of Alzheimer’s disease and epilepsy. Neurobiol Aging 35(9): 2091-5 (2014).
122. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90(5): 1977-81 (1993).
123. Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 16(9): 903-7 (2011).